Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases

Laura R. Rekedal, Elena Massarotti, Rajesh Garg, Radhika Bhatia, Timothy Gleeson, Bing Lu, Daniel H. Solomon

Research output: Contribution to journalArticlepeer-review

72 Scopus citations

Abstract

Objective: Prior research demonstrates that hydroxychloroquine (HCQ) lowers glycosylated hemoglobin (HbA 1c) in diabetes patients without rheumatic disease. We examined medical records of patients with diabetes mellitus (DM) and concomitant rheumatic illness to measure changes in HbA 1c after starting HCQ or methotrexate (MTX). Methods We used electronic medical records to identify patients beginning treatment with either HCQ or MTX who had a diagnosis of DM (or a pretreatment HbA 1c value of ≥7%) and at least 1 HbA 1c measurement both before and within 12 months after initiation of treatment. Using a structured medical record abstraction, we examined rheumatic disease diagnosis, cumulative steroid use, duration (months) between drug initiation and lowest HbA 1c value, a change in DM medication, body mass index (BMI), age, and sex. Adjusted linear regression models determined changes in HbA 1c from pretreatment values to the lowest posttreatment values within 12 months. Results We identified 45 patients taking HCQ and 37 patients taking MTX who met the inclusion criteria. Rheumatoid arthritis had been diagnosed in approximately half of the patients in each group. Age, sex, and mean pretreatment HbA 1c levels were similar across groups. The mean BMI of those taking HCQ (35.4 kg/m 2) was slightly higher than that of those taking MTX (32.2 kg/m 2) (P = 0.13). Glucocorticoid use appeared more common in those taking MTX (46%) than in those taking HCQ (29%) (P = 0.17). The mean reduction in HbA 1c from pretreatment values to the lowest posttreatment values was 0.66% (95% confidence interval [95% CI] 0.26, 1.05) in those taking HCQ compared with 0.11% (95% CI -0.18, 0.40) in those taking MTX. In fully adjusted analyses, the reduction in HbA 1c among those taking HCQ was 0.54% greater than the reduction among those taking MTX (P = 0.041). Conclusion HCQ initiation was associated with a significantly greater reduction in HbA 1c as compared with MTX initiation among diabetes patients with rheumatic disease.

Original languageEnglish (US)
Pages (from-to)3569-3573
Number of pages5
JournalArthritis Care and Research
Volume62
Issue number12
DOIs
StatePublished - Dec 2010
Externally publishedYes

ASJC Scopus subject areas

  • Rheumatology

Fingerprint

Dive into the research topics of 'Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases'. Together they form a unique fingerprint.

Cite this